Helsinn Healthcare SA

Pambio Noranco, Switzerland

Helsinn Healthcare SA

Pambio Noranco, Switzerland

Time filter

Source Type

Patent
Helsinn Healthcare SA | Date: 2016-09-30

The present invention provides crystalline forms of the chloride monohydrochloride salt of fosnetupitant, methods of making the crystalline forms, and pharmaceutical dosage forms that make use of the crystalline forms.


Patent
Helsinn Healthcare Sa | Date: 2016-12-02

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula I: or pharmaceutically acceptable salts thereof.


Patent
Helsinn Healthcare SA | Date: 2017-01-11

Disclosed are compounds, compositions and methods for the prevention and/or treatment of diseases which are pathophysiologically mediated by the ghrelin receptor. The compounds have the general Formula (I): or pharmaceutically acceptable salts thereof.


Patent
Helsinn Healthcare S.A. and Zealand Pharma A S | Date: 2017-07-19

The invention relates to the use of elsiglutide to prevent or reduce the occurrence of gastrointestinal damage caused by chemotherapeutic agents, including gastrointestinal mucositis and chemotherapy-induced diarrhea (CID).


Patent
Helsinn Healthcare SA | Date: 2017-07-12

Methods of treating cancer related conditions using anamorelin are described. The principal embodiment relates to the unique condition of patients defining this condition by treating cachexia in a human cancer patient, comprising administering to said patient a therapeutically effective amount of anamorelin for a therapeutically effective period of time, and observed surprising ability of anamorelin to increase lean body mass in this population.


Patent
Helsinn Healthcare SA | Date: 2017-08-02

The present invention is related to crystalline forms of 2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-(o-tolyl)pyridin-3-yl)propanamide which is an NK-1 antagonist useful in the treatment of induced vomiting and other disorders.


Patent
Helsinn Healthcare SA | Date: 2016-07-14

The present invention relates to shelf-stable liquid formulations of palonosetron for reducing chemotherapy and radiotherapy induced emesis with palonosetron. The formulations are particularly useful in the preparation of intravenous and oral liquid medicaments.


Patent
Helsinn Healthcare Sa and Ono Pharmaceutical Co. | Date: 2016-04-21

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.


Patent
Helsinn Healthcare Sa and Ono Pharmaceutical Co. | Date: 2016-04-21

The present invention relates to particulate forms of anamorelin monohydrochloride or a composition comprising anamorelin monohydrochloride having controlled chloride content, preferably isolated in an amorphous and/or fine particulate state, processes for making the particulate forms, and pharmaceutical compositions comprising the particulate forms.


Provided are compositions and methods for treating or preventing nausea and vomiting in patients undergoing chemotherapy, radiotherapy, or surgery.

Loading Helsinn Healthcare SA collaborators
Loading Helsinn Healthcare SA collaborators